Author

Melisa Tecik

Institution: Abdullah Gül University

Observed institutions: CEINGE Biotecnologie Avanzate Franco Salvatore (Italy), Abdullah Gül University

ORCID: 0000-0002-2485-6415

Observed ORCID: 0000-0002-2485-6415

OpenAlex ID: A5064246092

Therapeutic Targeting of FLT3 in Acute Myeloid Leukemia: Current Status and Novel Approaches

2022 · Melisa Tecik, Aysun Adan · OncoTargets and Therapy · 43

Emerging DNA Methylome Targets in FLT3-ITD-Positive Acute Myeloid Leukemia: Combination Therapy with Clinically Approved FLT3 Inhibitors

2024 · Melisa Tecik, Aysun Adan · Current Treatment Options in Oncology · 9

Concurrent inhibition of FLT3 and sphingosine kinase-1 triggers synergistic cytotoxicity in midostaurin resistant FLT3-ITD positive acute myeloid leukemia cells via blocking FLT3/STAT5A signaling to induce apoptosis

2025 · Melisa Tecik, Aysun Adan · Journal of Chemotherapy · 3

Dddr-32. a New Immunomodulatory Function of Pyrido-pyrimidine Derivatives to Impair Metastatic Group 3 Medulloblastoma in Vivo

2022 · Massimo Zollo, Fatemeh Asadzadeh, et al. · Neuro-Oncology · 1

Functional combination of resveratrol and midostaurin induces cytotoxicity to overcome acquired midostaurin resistance in FLT3-ITD expressing acute myeloid leukemia cells

2025 · Melisa Tecik, Aysun Adan · Naunyn-Schmiedeberg s Archives of Pharmacology

Works count: 5

Citation count: 56

H-index: 3

I10-index: 1